{"slug":"ctdna-roadmap","tag":"ctdna-roadmap","variants":["ctdna-roadmap"],"description":"No description yet","count":6,"kinds":{"trial":6},"related":[],"records":[{"id":"tracc","kind":"trial","name":"TRACC","route":"/trials/tracc/","status":"recruiting","tldr":"A UK study following 1,000 people after bowel cancer surgery with repeated blood tests for tumour DNA, to see how well a positive predicts the cancer coming back and whether the result can guide chemotherapy."},{"id":"bespoke-crc","kind":"trial","name":"BESPOKE CRC","route":"/trials/bespoke-crc/","status":"active","tldr":"Natera's US study in which 1,788 people with bowel cancer had Signatera blood tests after surgery and their doctors could act on the result; it records what changed and what happened, but does not randomise anyone."},{"id":"mermaid-1","kind":"trial","name":"MERMAID-1","route":"/trials/mermaid-1/","status":"completed","tldr":"A lung cancer trial that planned to test whether adding the immunotherapy durvalumab to chemotherapy after surgery helps people whose blood shows leftover tumour DNA; the registry lists it as complete with 89 participants."},{"id":"mermaid-2","kind":"trial","name":"MERMAID-2","route":"/trials/mermaid-2/","status":"completed","tldr":"A lung cancer trial that planned to start durvalumab the moment a surveillance blood test found tumour DNA, before any scan showed relapse; the registry lists it as complete with 30 participants."},{"id":"circulate-us","kind":"trial","name":"CIRCULATE-US","route":"/trials/circulate-us/","status":"recruiting","tldr":"The US national trial that uses a blood test for leftover tumour DNA to decide who gets less chemotherapy and who gets more after stage III colon cancer surgery, with both questions randomised."},{"id":"vanguard-study","kind":"trial","name":"Vanguard Study (NCI Cancer Screening Research Network)","route":"/trials/vanguard-study/","status":"recruiting","tldr":"The US government's first randomised study of multi-cancer blood tests: 24,000 people are being assigned to a blood test or usual care to work out how a much larger trial should be run."}]}